

Asco 2023 story roundup



[Jacob Plieth](#)

Evaluate Vantage and *Scrip* have been reporting from the Asco 2023 meeting and have covered the following stories:

8 June:

[Asco 2023 movers - maintaining the momentum](#)

7 June:

[Novocure sinks as Lunar's limitations become clear](#)

6 June:

[Dizal heralds a "super-Tagrisso"](#)

[Early first-line lung cancer data mined for datopotamab gold](#)

5 June:

[Enhertu hits with pan approach](#)

[Bicara eyes head and neck niche](#)

[Regeneron nips at Bristol's heels in Lag3](#)

[Adaura survival boost for AZ's Tagrisso \(*Scrip*\)](#)

4 June:

[Roche sees Morpheus and takes the red pill](#)

[Liver tox casts a pall over Servier's Indigo readout](#)

[Trop2 could validate Merck's savvy deal with Kelun](#)

[Deep and early responses lift hopes at Effector](#)

[Immunogen's Elahere data in avastin-naïve ovarian cancer prompt discussion about earlier use \(*Scrip*\)](#)

3 June:

[Pfizer pushes forward in drug-resistant breast cancer](#)

[Six months on Gilead/Arcus's Tigit deflates](#)

[Elevation follows in Astellas's slipstream](#)

[A role for immuno-oncology in ovarian cancer at last](#)

[Jazz hits high note with updated zanidatamab data in biliary tract cancer \(Scrip\)](#)

2 June:

[Novartis's adjuvant breast cancer win comes with caveats](#)

[Commands leaves the door open for Geron](#)

30 May:

[Tigit lives again](#)

[A microcap winner](#)

The article on Servier's Indigo trial was jointly authored by Scrip's [Alex Shimmings](#). Scrip and Evaluate Vantage are part of the same parent company, Norstellia.

In addition, Jacob Plieth spoke with Brad Loncar on BiotechTV to preview the conference:

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](#)

Evaluate Americas
[+1-617-573-9450](#)

Evaluate APAC
[+81-\(0\)80-1164-4754](#)

© Copyright 2023 Evaluate Ltd.